What pharmacologic options can be used to manage secretions and the death rattle in terminally ill patients?

Study for ELNEC 4: Symptom Management in Palliative Care Test with flashcards and multiple choice questions. Hints and explanations included! Get ready for your exam!

Managing secretions that cause the death rattle relies on medicines that specifically reduce mucous production in the airways. The best approach uses anticholinergic (antimuscarinic) agents that dry secretions from salivary and bronchial glands, helping to lessen both the audible rattle and patient distress.

Glycopyrrolate is often preferred because it reduces secretions with minimal central nervous system effects, lowering the risk of confusion. Scopolamine patches provide a steady, long-acting anticholinergic effect, which can be convenient for ongoing control. Atropine is another option for faster, short-term effect. These drugs can be given by oral, subcutaneous, intravenous, or transdermal routes, depending on the situation and patient needs.

Nonpharmacologic measures remain important and include careful positioning and oral care to keep the patient comfortable. Suctioning should be used sparingly, as it can be distressing and may not improve comfort in all cases. If secretions remain distressing despite anticholinergics and nonpharmacologic efforts, sedation to relieve distress can be considered, with goals aligned to patient comfort and family wishes.

Antibiotics, intravenous sedatives, or nebulized bronchodilators do not directly address the death rattle, and are not first-line options for this symptom unless there is a separate, treatable condition (like infection or bronchospasm) contributing to distress. Side effects to monitor include dry mouth, urinary retention, constipation, tachycardia, and potential delirium, especially in susceptible individuals.